Two Chinese life sciences companies announced a strategic partnership on July 6 that marks a first for China’s nuclear medicine sector: Sanyou Bio, an AI-driven drug discovery platform, and Baiyunshan Xihe Alliance, a nuclear medicine manufacturing specialist, will jointly develop radiopharmaceuticals and radiodiagnostic products using AI-accelerated research methods. According to BioPharmaAPAC, the collaboration is the first major AI-drug discovery partnership in China’s nuclear medicine industry, a sector that has historically relied on conventional chemistry and manual research workflows.
Radiopharmaceuticals occupy a specialized niche within drug development. They are compounds that incorporate radioactive isotopes, used both for diagnostic imaging (where the radioactive tracer allows doctors to visualize biological processes in real time) and for targeted cancer therapy (where the radioactive payload is delivered directly to tumor cells). The development process is technically demanding, radioactive compounds have short half-lives that constrain the time available for synthesis and testing, and the regulatory requirements for nuclear medicine products are among the most stringent in the pharmaceutical industry.
(Related: China’s Domestic AI Chips Have Entered the Training Stack — and the Efficiency Gap Is Closing)
What AI Brings to Radiopharmaceutical Development
The application of AI to radiopharmaceutical development addresses several of the sector’s most persistent bottlenecks. Molecular design, identifying which compounds are likely to bind effectively to target receptors while incorporating a radioactive isotope in a chemically stable configuration, is a combinatorial problem that is well-suited to AI-based screening. Traditional approaches rely on chemists manually evaluating candidate molecules; AI platforms can screen millions of candidates computationally in the time it would take a human team to evaluate hundreds.
Sanyou Bio’s platform is built around generative AI models trained on large datasets of molecular structures, binding affinities, and pharmacokinetic properties. The platform can propose novel molecular structures optimized for specific target profiles, predict their likely behavior in biological systems, and prioritize candidates for laboratory synthesis and testing. Applied to radiopharmaceuticals, this capability could significantly shorten the time from target identification to clinical candidate, a process that currently takes years in conventional drug development.
Baiyunshan Xihe Alliance brings the manufacturing expertise to translate AI-designed candidates into actual compounds. Nuclear medicine manufacturing requires specialized facilities, including hot cells, radiation shielding, and isotope-handling equipment. These are expensive to build and operate, and Baiyunshan Xihe is one of a small number of Chinese companies with the infrastructure to manufacture radiopharmaceuticals at commercial scale. The partnership combines Sanyou’s computational design capabilities with Baiyunshan’s manufacturing infrastructure, creating a vertically integrated pipeline from molecular design to the production of clinical-grade compounds.
(Related: State Council Sets Agenda: AI Breakthroughs, Balanced Trade, and Green Economy)
The Strategic Context: China’s Nuclear Medicine Ambitions
China’s nuclear medicine sector has been growing rapidly, driven by rising cancer incidence, expanding hospital infrastructure, and government investment in medical imaging and oncology. The country has been working to reduce its dependence on imported radiopharmaceuticals, particularly diagnostic tracers and therapeutic isotopes, by building domestic production capacity and developing homegrown compounds.
The Sanyou-Baiyunshan partnership fits within this broader strategic context. By applying AI to accelerate the development of novel radiopharmaceuticals, the collaboration could help China build a pipeline of domestically developed nuclear medicine products that reduce import dependence and give Chinese patients access to treatments currently available only from foreign manufacturers. The nuclear medicine sector is also one where China has a potential competitive advantage: the country has significant isotope production capacity through its network of research reactors, which could supply the raw materials for a domestic radiopharmaceutical industry at scale.
The announcement on July 6 does not include specific product targets, timelines, or financial terms, details that are typical of early-stage strategic partnerships in the pharmaceutical industry. But the significance of the deal lies less in its immediate specifics than in what it signals about the direction of China’s AI-in-healthcare strategy: moving beyond the general-purpose AI diagnostic tools that have dominated the sector for the past several years into specialized, high-value therapeutic applications where the barriers to entry are higher and the commercial opportunities are larger.
AI Drug Discovery in China: From General to Specialized
The Sanyou-Baiyunshan partnership represents a maturation of China’s AI drug discovery sector. The first wave of AI-in-pharma activity in China, which peaked around 2022 to 2024, was dominated by companies applying general-purpose AI tools to large-scale molecular screening across broad therapeutic areas. The results were mixed: AI-assisted screening accelerated early-stage candidate identification, but the bottleneck shifted downstream to clinical development, where AI’s advantages are less pronounced, and the costs are dominated by human trials rather than computational work.
The second wave, of which the Sanyou-Baiyunshan deal is an example, is characterized by specialization. Rather than applying AI broadly across all of drug discovery, companies are identifying specific sub-sectors, including nuclear medicine, rare diseases, and biologics, where AI’s advantages are most pronounced and where the competitive landscape is less crowded. Radiopharmaceuticals are a particularly attractive target because the field’s technical complexity has historically limited the number of companies that can participate, and AI tools that reduce that complexity could unlock a large addressable market.
China’s regulatory environment is also evolving in ways that support this kind of specialized AI-drug development. The National Medical Products Administration has been developing frameworks for AI-assisted drug development that provide clearer guidance on what kinds of AI-generated data can be submitted as part of regulatory filings, a prerequisite for AI-developed drugs to reach clinical trials. As those frameworks mature, the commercial case for AI drug discovery partnerships, such as the one between Sanyou and Baiyunshan, will strengthen further.